University of Texas's MD Anderson Cancer: Study Finds High Tumor Mutation Burden Predicts Immunotherapy Response in Some, But Not All, Cancers
March 16, 2021
March 16, 2021
HOUSTON, Texas, March 16 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on March 15, 2021:
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a new study led by researchers from The University of Texas MD Anderson Cancer Center.
The findings, published . . .
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a new study led by researchers from The University of Texas MD Anderson Cancer Center.
The findings, published . . .